Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection
In fecal microbiota transplantation (FMT) against recurrent Clostridioides difficile infection (CDI), clinical outcomes are usually determined after 8 weeks. We hypothesized that the intestinal microbiota changes earlier than this timepoint, and analyzed fecal samples obtained 1 week after treatment...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2084306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850109140810072064 |
|---|---|
| author | Shaodong Wei Martin Iain Bahl Simon Mark Dahl Baunwall Jens Frederik Dahlerup Christian Lodberg Hvas Tine Rask Licht |
| author_facet | Shaodong Wei Martin Iain Bahl Simon Mark Dahl Baunwall Jens Frederik Dahlerup Christian Lodberg Hvas Tine Rask Licht |
| author_sort | Shaodong Wei |
| collection | DOAJ |
| description | In fecal microbiota transplantation (FMT) against recurrent Clostridioides difficile infection (CDI), clinical outcomes are usually determined after 8 weeks. We hypothesized that the intestinal microbiota changes earlier than this timepoint, and analyzed fecal samples obtained 1 week after treatment from 64 patients diagnosed with recurrent CDI and included in a randomized clinical trial, where the infection was treated with either vancomycin-preceded FMT (N = 24), vancomycin (N = 16) or fidaxomicin (N = 24). In comparison with non-responders, patients with sustained resolution after FMT had increased microbial alpha diversity, enrichment of Ruminococcaceae and Lachnospiraceae, depletion of Enterobacteriaceae, more pronounced donor microbiota engraftment, and resolution of gut microbiota dysbiosis. We found that a constructed index, based on markers for the identified genera Escherichia and Blautia, successfully predicted clinical outcomes at Week 8, which exemplifies a way to utilize clinically feasible methods to predict treatment failure. Microbiota changes were restricted to patients who received FMT rather than antibiotic monotherapy, indicating that FMT confers treatment response in a different way than antibiotics. We suggest that early identification of microbial community structures after FMT is of clinical value to predict response to the treatment. |
| format | Article |
| id | doaj-art-40395e48d60f42fd9993ae8dd1fd962f |
| institution | OA Journals |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-40395e48d60f42fd9993ae8dd1fd962f2025-08-20T02:38:10ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2084306Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infectionShaodong Wei0Martin Iain Bahl1Simon Mark Dahl Baunwall2Jens Frederik Dahlerup3Christian Lodberg Hvas4Tine Rask Licht5National Food Institute, Technical University of Denmark, Kgs Lyngby, DenmarkNational Food Institute, Technical University of Denmark, Kgs Lyngby, DenmarkDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N, DenmarkDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N, DenmarkDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus N, DenmarkNational Food Institute, Technical University of Denmark, Kgs Lyngby, DenmarkIn fecal microbiota transplantation (FMT) against recurrent Clostridioides difficile infection (CDI), clinical outcomes are usually determined after 8 weeks. We hypothesized that the intestinal microbiota changes earlier than this timepoint, and analyzed fecal samples obtained 1 week after treatment from 64 patients diagnosed with recurrent CDI and included in a randomized clinical trial, where the infection was treated with either vancomycin-preceded FMT (N = 24), vancomycin (N = 16) or fidaxomicin (N = 24). In comparison with non-responders, patients with sustained resolution after FMT had increased microbial alpha diversity, enrichment of Ruminococcaceae and Lachnospiraceae, depletion of Enterobacteriaceae, more pronounced donor microbiota engraftment, and resolution of gut microbiota dysbiosis. We found that a constructed index, based on markers for the identified genera Escherichia and Blautia, successfully predicted clinical outcomes at Week 8, which exemplifies a way to utilize clinically feasible methods to predict treatment failure. Microbiota changes were restricted to patients who received FMT rather than antibiotic monotherapy, indicating that FMT confers treatment response in a different way than antibiotics. We suggest that early identification of microbial community structures after FMT is of clinical value to predict response to the treatment.https://www.tandfonline.com/doi/10.1080/19490976.2022.2084306Clostridioides difficilefecal microbiota transplantationfidaxomicingut microbiotavancomycin |
| spellingShingle | Shaodong Wei Martin Iain Bahl Simon Mark Dahl Baunwall Jens Frederik Dahlerup Christian Lodberg Hvas Tine Rask Licht Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection Gut Microbes Clostridioides difficile fecal microbiota transplantation fidaxomicin gut microbiota vancomycin |
| title | Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection |
| title_full | Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection |
| title_fullStr | Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection |
| title_full_unstemmed | Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection |
| title_short | Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection |
| title_sort | gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent clostridioides difficile infection |
| topic | Clostridioides difficile fecal microbiota transplantation fidaxomicin gut microbiota vancomycin |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2084306 |
| work_keys_str_mv | AT shaodongwei gutmicrobiotadiffersbetweentreatmentoutcomesearlyafterfecalmicrobiotatransplantationagainstrecurrentclostridioidesdifficileinfection AT martiniainbahl gutmicrobiotadiffersbetweentreatmentoutcomesearlyafterfecalmicrobiotatransplantationagainstrecurrentclostridioidesdifficileinfection AT simonmarkdahlbaunwall gutmicrobiotadiffersbetweentreatmentoutcomesearlyafterfecalmicrobiotatransplantationagainstrecurrentclostridioidesdifficileinfection AT jensfrederikdahlerup gutmicrobiotadiffersbetweentreatmentoutcomesearlyafterfecalmicrobiotatransplantationagainstrecurrentclostridioidesdifficileinfection AT christianlodberghvas gutmicrobiotadiffersbetweentreatmentoutcomesearlyafterfecalmicrobiotatransplantationagainstrecurrentclostridioidesdifficileinfection AT tinerasklicht gutmicrobiotadiffersbetweentreatmentoutcomesearlyafterfecalmicrobiotatransplantationagainstrecurrentclostridioidesdifficileinfection |